Shakir and colleagues [24] also reported that above a PSA threshold of 5.2 ng/ml there were more upgrades to clinically significant prostate cancer by MR/US fusion biopsy compared with systematic biopsy. The gene discussed is KLK3; the disease is prostate cancer.